About ImmunoACT
ImmunoACT is a company based in Mumbai (India) founded in 2018 by Atharva Karulkar and Rahul Purwar.. ImmunoACT has raised $15.87 million across 5 funding rounds from investors including Laurus Labs and SINE. The company has 69 employees as of April 07, 2024. ImmunoACT offers products and services including NexCAR19. ImmunoACT operates in a competitive market with competitors including Adicet Bio, Orca Bio, Ossium Health, Nordic Nanovector and Kiadis Pharma, among others.
- Headquarter Mumbai, India
- Employees 69 as on 07 Apr, 2024
- Founders Atharva Karulkar, Rahul Purwar
- Stage Minicorn
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Immunoadoptive Cell Therapy Private Limited
- Date of Incorporation 08 Oct, 2018
- Jurisdiction Mumbai, Maharashtra, India
-
Annual Revenue
$1.29 M (USD)1454.31as on Mar 31, 2024
-
Net Profit
$-1.77 M (USD)-46.6as on Mar 31, 2024
-
EBITDA
$-1.33 M (USD)-92.92as on Mar 31, 2024
-
Total Equity Funding
$15.87 M (USD)
in 5 rounds
-
Latest Funding Round
$9.67 M (USD), Series B
May 31, 2023
-
Investors
Laurus Labs
& 1 more
-
Employee Count
69
as on Apr 07, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ImmunoACT
ImmunoACT offers a comprehensive portfolio of products and services, including NexCAR19. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Modifies T-cells to target and eliminate cancer cells in patients.
Unlock access to complete
Unlock access to complete
Funding Insights of ImmunoACT
ImmunoACT has successfully raised a total of $15.87M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $9.67 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series B — $9.7M
- First Round First Round
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2023 | Amount | Series B - ImmunoACT | Valuation | Laurus Labs |
|
| Nov, 2021 | Amount | Series A - ImmunoACT | Valuation |
investors |
|
| Oct, 2021 | Amount | Seed - ImmunoACT | Valuation | SINE |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in ImmunoACT
ImmunoACT has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include Laurus Labs and SINE. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Sector-agnostic startups are accelerated by SINE, backed by IIT Bombay.
|
Founded Year | Domain | Location | |
|
Pharmaceutical and biotechnology company
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by ImmunoACT
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - ImmunoACT
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Immunoact Comparisons
Competitors of ImmunoACT
ImmunoACT operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adicet Bio, Orca Bio, Ossium Health, Nordic Nanovector and Kiadis Pharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Immune cell therapies for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders
|
|
| domain | founded_year | HQ Location |
Ossium Health is focused on bioengineering for improved health.
|
|
| domain | founded_year | HQ Location |
Antibody radionuclide conjugates are developed for haematological cancers.
|
|
| domain | founded_year | HQ Location |
Therapeutic solutions for hematopoietic stem cell transplants are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Immunoact
Frequently Asked Questions about ImmunoACT
When was ImmunoACT founded?
ImmunoACT was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Where is ImmunoACT located?
ImmunoACT is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
Is ImmunoACT a funded company?
ImmunoACT is a funded company, having raised a total of $15.87M across 5 funding rounds to date.
How many employees does ImmunoACT have?
As of Apr 07, 2024, the latest employee count at ImmunoACT is 69.
What is the annual revenue of ImmunoACT?
Annual revenue of ImmunoACT is $1.29M as on Mar 31, 2024.
What does ImmunoACT do?
ImmunoACT was established in 2018 in Mumbai, India, within the biotechnology sector. Cell therapies targeting cancer are developed using a patented CAR-T platform that incorporates a design algorithm for pipeline candidates. These include Actalycabtagene autoleucel for B-lymphoid malignancies, HCAR2 for multiple myeloma, and HCAR3 for glioblastoma multiforme and neuroblastoma. Focus is placed on immuno-oncology advancements.
Who are the top competitors of ImmunoACT?
ImmunoACT's top competitors include Orca Bio, Ossium Health and Adicet Bio.
What products or services does ImmunoACT offer?
ImmunoACT offers NexCAR19.
Who are ImmunoACT's investors?
ImmunoACT has 2 investors. Key investors include Laurus Labs, and SINE.
What is ImmunoACT's valuation?
The valuation of ImmunoACT is $10.81M as of Oct 2021.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.